Strongyloidiasis prophylaxis: is there room for ivermectin in neurological patients?

AbstractWith the advent of monoclonal therapies, there is currently an array of treatment options for autoimmune neurological disorders involving the use of immunosuppressive and immunomodulatory drugs; nevertheless, these therapies may predispose patients to the hyperinfection syndrome (HS) caused by strongyloidiasis, leading to severe manifestations1. For this reason, a prophylactic treatment with ivermectin has been proposed for patients from endemic regions undergoing immunosuppressive treatment2,3. However, there is no evidence in the literature that supports that recommendation.

Source: Clinical and Experimental Neuroimmunology - August 18, 2021 Category: Neurology Authors: Marcelo Henrique De Moura Campos, Ariel Jos é Gomes Marques Neto, Rodrigo Kleinpaul, Marcus Vinicius Magno Gonçalves Tags: LETTER TO THE EDITOR Source Type: research